Trial Profile
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Pegfilgrastim
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Jun 2020 Primary endpoint (Overall Survival (OS)) has not been met as per results published in the Clinical Cancer Research.
- 26 Jun 2020 Results published in the Clinical Cancer Research
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.